Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the closing of its Series B round with $40 million in new investment. The proceeds from this financing will be used to develop new treatments for rare genetic diseases, and to expand the company’s proprietary AI discovery platform to support the discovery … Read More